Kyntra Bio
KYNB
175 hedge funds and large institutions have $1.8B invested in Kyntra Bio in 2021 Q2 according to their latest regulatory filings, with 32 funds opening new positions, 54 increasing their positions, 54 reducing their positions, and 54 closing their positions.
13% more call options, than puts
Call options by funds: $77.3M | Put options by funds: $68.3M
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0% more repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 54
0.19% less ownership
Funds ownership: 3.13% → 2.94% (-0.19%)
12% less funds holding
Funds holding: 198 → 175 (-23)
27% less capital invested
Capital invested by funds: $2.47B → $1.8B (-$666M)
41% less first-time investments, than exits
New positions opened: 32 | Existing positions closed: 54
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Trust Advisors
Wheaton,
Illinois
|
+$34M |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$21.6M |
| 3 |
Primecap Management
Pasadena,
California
|
+$17.8M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$10.6M |
| 5 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
+$9.79M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$48.1M |
| 2 |
Janus Henderson Group
London,
|
-$47.5M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$32.3M |
| 4 |
Brown Advisory
Baltimore,
Maryland
|
-$27.9M |
| 5 |
Fiera Capital (Canada)
Montreal,
Quebec, Canada
|
-$14.3M |
KYNB Hedge Fund Activity: Q2 2021 in Review
175 of the 5,766 institutional investors tracked by Wall St. Rank reported a position in Kyntra Bio (KYNB) for Q2 2021, worth a combined $1.8B — down 27% from $2.47B a quarter earlier.
Sellers outnumbered buyers: 54 funds closed out of KYNB and 32 opened new positions — a net loss of 22 holders — while 54 trimmed existing stakes and 54 added.
The largest buyer was First Trust Advisors, adding an estimated $34M. The largest seller was Fidelity Investments, cutting an estimated $48.1M.
- 175 institutional investors held Kyntra Bio (KYNB) as of Q2 2021, down from 198 in Q1 2021.
- Funds reported $1.8B of Kyntra Bio stock for Q2 2021, down 27% quarter-over-quarter.
- 32 funds opened new Kyntra Bio positions in Q2 2021 and 54 closed out, a net change of -22 holders.
- The largest Kyntra Bio buyer in Q2 2021 was First Trust Advisors, an estimated $34M added.
- The largest Kyntra Bio seller in Q2 2021 was Fidelity Investments, an estimated $48.1M sold.
Based on aggregated 13F filings for Q2 2021.